Based on hormone-receptor and HER2-negative cancer specimen showing abundant NDRG2 expression, we hypothesized that the described NDRG2 expression loss and thus a putative tumor suppressive function of NDRG2 may be confined to luminal-type breast cancers. Here, ERBB2 is linked to breast cancer.